Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02441322 · ClinicalTrials.gov registry record · NA
Evaluating Therapeutic Response to Novo-TTF
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02441322 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 30 participants.
The verdict
NCT02441322, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is to assess the utility of high resolution 3D echo planar magnetic resonance spectroscopy (3D EPSI) in monitoring Novo-TTF response in glioblastoma multiforme (GBM) patients.
Interventions
- DEVICE Novo-TTF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-12 |
| Est. Completion | 2023-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02441322
The ClinicalTrials.gov registry entry for NCT02441322 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Novo-TTF is the first listed.
NCT02441322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02441322 about?
NCT02441322 is a clinical study titled "Evaluating Therapeutic Response to Novo-TTF". This study is to assess the utility of high resolution 3D echo planar magnetic resonance spectroscopy (3D EPSI) in monitoring Novo-TTF response in glioblastoma multiforme (GBM) patients.
What is the current status of trial NCT02441322?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-12. Estimated completion is 2023-12.
What interventions are being tested in trial NCT02441322?
The interventions under investigation include: Novo-TTF (DEVICE).
Who is sponsoring clinical trial NCT02441322?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.